2-chloro-5-(2-fluoroethylthio)aniline | 1220982-13-7

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 2-chloro-5-(2-fluoroethylthio)aniline
• 英文别名: 2-chloro-5-((2-fluoroethyl)mercapto)aniline；2-chloro-5-(S-2-fluoroethyl)thioaniline；2-Chloro-5-(2-fluoroethylsulfanyl)aniline；2-chloro-5-(2-fluoroethylsulfanyl)aniline
• CAS: 1220982-13-7
• 化学式: C₈H₉ClFNS
• 分子量: 205.684
• InChiKey: XXVHUWPKVPOQRY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  51.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-chloro-5-(2-fluoroethylthio)aniline 在 盐酸羟胺 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 48.0h， 生成 (E)-1-(2-chloro-5-((2-fluoroethyl)mercapto)phenyl)-2-hydroxy-3-(3-(methylthio)phenyl)guanidine
  参考文献：
  名称：

  一种2-羟基胍类化合物及其制备方法

  摘要：

  本发明公开了一种2‑羟基胍类化合物，该2‑羟基胍类化合物具有如通式(Ⅰ)所示结构的化合物及其可药用盐，其中，R1和R2表示苯环上邻、间、对位上单取代或多取代的硝基/烷基、取代或未取代的巯基、取代或未取代的氨基、取代或未取代的羟基、卤素中的一种或几种。本发明还公开该化合物的制备方法和该2‑羟基胍类化合物在制备NMDAR表达异常的诊断试剂和NMDAR表达异常所致疾病的治疗药物中的应用。本发明提供的2‑羟基胍类化合物具有良好的NMDAR结合活性，可应用于制备NMDAR表达异常的诊断试剂和NMDAR表达异常所致疾病的治疗药物。

  公开号：

  CN111170895B
• 作为产物：
  描述：

  4-氯-3-硝基苯磺酰氯 在 盐酸 、 tin(II) chloride dihdyrate 、 potassium carbonate 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 2-chloro-5-(2-fluoroethylthio)aniline
  参考文献：
  名称：

  N′-3-(Trifluoromethyl)phenyl Derivatives of N-Aryl-N′-methylguanidines as Prospective PET Radioligands for the Open Channel of the N-Methyl-d-aspartate (NMDA) Receptor: Synthesis and Structure–Affinity Relationships

  摘要：

  N-Methyl-D-aspartate (NMDA) receptor dysfunction has been linked to several neuropsychiatric disorders, including Alzheimer's disease, epilepsy, drug addiction, and schizophrenia. A radioligand that could be used with PET to image and quantify human brain. NMDA receptors in the activated "open channel" state would be useful for research on such disorders and for the development of novel therapies,: To date, no radioligands have Shown well-validated efficacy for imaging NMDA receptors in human subjects. In order to discover improved radioligands for PET imaging, we explored structure affinity relationships in N'-3-(trifluoromethyl)phenyl derivatives of N-aryl-N'-methylguanidines, seeking high affinity and moderate lipophilicity, plus necessary amenability for labeling with a positron-emitter, either carbon-11 or fluorine-18. Among a diverse set of 80 prepared N'-3-(trifluoromethyl)phenyl derivatives, four of these compounds (13, 19, 20, and 36) displayed desirable low nanomolar affinity for inhibition of [H-3](+)-MK801 at the PCP binding site and are of interest for candidate PET radioligand development.

  DOI：

  10.1021/acs.jmedchem.5b01510

文献信息

• Synthesis and in vitro evaluation of 18F-labelled S-fluoroalkyl diarylguanidines: Novel high-affinity NMDA receptor antagonists for imaging with PET
  作者：Edward G. Robins、Yongjun Zhao、Imtiaz Khan、Anthony Wilson、Sajinder K. Luthra、Erik Årstad

  DOI：10.1016/j.bmcl.2010.01.052

  日期：2010.3

  Two S-[18F]fluoroalkylated diarylguanidines were synthesized and evaluated in vitro as potential tracers for imaging of N-methyl-d-aspartate receptors (NMDARs) with positron emission tomography (PET). [18F]1 and [18F]10 were synthesized by [18F]fluoroethylation and [18F]fluoromethylation of the thiol precursor 6, respectively. [18F]1 is a promising candidate NMDAR PET tracer, with low nanomolar affinity

  两个小号- [ 18 F]氟烷基diarylguanidines合成和体外评价为成像潜在示踪剂Ñ甲基d天冬氨酸受体（NMDAR的）与正电子发射断层扫描（PET）。通过硫醇前体6的[ 18 F]氟乙基化和[ 18 F]氟甲基化分别合成[ 18 F] 1和[ 18 F] 10。[ 18 F] 1是一种有前途的候选NMDAR PET示踪剂，对NMDA PCP部位的纳摩尔亲和力低，选择性高且亲脂性中等。
• <i>N</i>′-3-(Trifluoromethyl)phenyl Derivatives of <i>N</i>-Aryl-<i>N</i>′-methylguanidines as Prospective PET Radioligands for the Open Channel of the <i>N</i>-Methyl-<scp>d</scp>-aspartate (NMDA) Receptor: Synthesis and Structure–Affinity Relationships
  作者：Gregory R. Naumiec、Kimberley J. Jenko、Sami S. Zoghbi、Robert B. Innis、Lisheng Cai、Victor W. Pike

  DOI：10.1021/acs.jmedchem.5b01510

  日期：2015.12.24

  N-Methyl-D-aspartate (NMDA) receptor dysfunction has been linked to several neuropsychiatric disorders, including Alzheimer's disease, epilepsy, drug addiction, and schizophrenia. A radioligand that could be used with PET to image and quantify human brain. NMDA receptors in the activated "open channel" state would be useful for research on such disorders and for the development of novel therapies,: To date, no radioligands have Shown well-validated efficacy for imaging NMDA receptors in human subjects. In order to discover improved radioligands for PET imaging, we explored structure affinity relationships in N'-3-(trifluoromethyl)phenyl derivatives of N-aryl-N'-methylguanidines, seeking high affinity and moderate lipophilicity, plus necessary amenability for labeling with a positron-emitter, either carbon-11 or fluorine-18. Among a diverse set of 80 prepared N'-3-(trifluoromethyl)phenyl derivatives, four of these compounds (13, 19, 20, and 36) displayed desirable low nanomolar affinity for inhibition of [H-3](+)-MK801 at the PCP binding site and are of interest for candidate PET radioligand development.
• 一种2-羟基胍类化合物及其制备方法
  申请人：复旦大学附属华山医院

  公开号：CN111170895B

  公开（公告）日：2023-04-14

  本发明公开了一种2‑羟基胍类化合物，该2‑羟基胍类化合物具有如通式(Ⅰ)所示结构的化合物及其可药用盐，其中，R1和R2表示苯环上邻、间、对位上单取代或多取代的硝基/烷基、取代或未取代的巯基、取代或未取代的氨基、取代或未取代的羟基、卤素中的一种或几种。本发明还公开该化合物的制备方法和该2‑羟基胍类化合物在制备NMDAR表达异常的诊断试剂和NMDAR表达异常所致疾病的治疗药物中的应用。本发明提供的2‑羟基胍类化合物具有良好的NMDAR结合活性，可应用于制备NMDAR表达异常的诊断试剂和NMDAR表达异常所致疾病的治疗药物。